The Latin America, Middle East and Africa Biodefense Market is expected to witness market growth of 6.7% CAGR during the forecast period (2020-2026).
Biodefense is referred to the exhaustive steps (identification, planning, and preparedness) employed to re-establish the biosecurity of a nation with respect to biological threats or infectious diseases. Also, these weapons can be used to initiate bioterrorism and social upheaval. The origin of biological threats could be accidental, deliberate, or naturally occurring. Supportive government initiatives, huge investment by private players, and the increasing prevalence of different viral agents are some of the major factors boosting the market growth.
Increased awareness about bioterrorism attacks in various developed economies, will fuel the development of the global biodefense market over the forecast period. These attacks are considered as the process of intentional release of bacteria, viruses, and other harmful microbes, that are capable of bring devastation.
Such a situation creates a destructive impact on the economy and human life & health. Moreover, it results in the depletion of human resources. Due to this scenario, the government in the developed economies undertakes various initiatives coupled with preventive measures to manage these attacks. This factor is anticipated to encourage the growth of the biodefense market during the forecast period.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
By Country
Companies Profiled
Unique Offerings from the Publisher
Biodefense is referred to the exhaustive steps (identification, planning, and preparedness) employed to re-establish the biosecurity of a nation with respect to biological threats or infectious diseases. Also, these weapons can be used to initiate bioterrorism and social upheaval. The origin of biological threats could be accidental, deliberate, or naturally occurring. Supportive government initiatives, huge investment by private players, and the increasing prevalence of different viral agents are some of the major factors boosting the market growth.
Increased awareness about bioterrorism attacks in various developed economies, will fuel the development of the global biodefense market over the forecast period. These attacks are considered as the process of intentional release of bacteria, viruses, and other harmful microbes, that are capable of bring devastation.
Such a situation creates a destructive impact on the economy and human life & health. Moreover, it results in the depletion of human resources. Due to this scenario, the government in the developed economies undertakes various initiatives coupled with preventive measures to manage these attacks. This factor is anticipated to encourage the growth of the biodefense market during the forecast period.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/nuclear,
- Other Products
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA Biodefense Market by Product
Chapter 5. LAMEA Biodefense Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Methodology
LOADING...
